Target Gene/Pathway Pathway / Gene

  

Search results

No. KEGG PATHWAY
On map, Yellow: Drug target, Red: All disease-related 		KEGG GENES KEGG DRUG DrugBank 指定難病告示番号
1 Adherens junction 💬
 1件: FGFR1 💬 D10481 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
2 Adipocytokine signaling pathway 💬
 1件: TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
3 Adipocytokine signaling pathway 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
4 Adrenergic signaling in cardiomyocytes 💬
 2件: ADRB1, ADRB2 💬 D00483 💬 Propranolol 7件:  6 , 158, 167, 215, 227, 278, 296 💬
5 Adrenergic signaling in cardiomyocytes 💬
 2件: ADRB1, ADRB2 💬 D08443 💬 Propranolol 7件:  6 , 158, 167, 215, 227, 278, 296 💬
6 Adrenergic signaling in cardiomyocytes 💬
 2件: ADRB1, ADRB2 💬 D00378 💬 Timolol 2件: 157, 227 💬
7 Adrenergic signaling in cardiomyocytes 💬
 2件: ADRB1, ADRB2 💬 D00603 💬 Timolol 2件: 157, 227 💬
8 Adrenergic signaling in cardiomyocytes 💬
 2件: ADRB1, ADRB2 💬 D08600 💬 Timolol 2件: 157, 227 💬
9 African trypanosomiasis 💬
 2件: IL6, TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
10 African trypanosomiasis 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
11 AGE-RAGE signaling pathway in diabetic complications 💬
 2件: IL6, TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
12 AGE-RAGE signaling pathway in diabetic complications 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
13 AGE-RAGE signaling pathway in diabetic complications 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
14 AGE-RAGE signaling pathway in diabetic complications 💬
 1件: VEGFA 💬 D05697 💬 Ranibizumab 4件: 34, 166, 227, 301 💬
15 Alcoholic liver disease 💬
 2件: IL6, TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
16 Alcoholic liver disease 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
17 Allograft rejection 💬
 1件: TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
18 Allograft rejection 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
19 Alzheimer disease 💬
 2件: IL6, TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
20 Alzheimer disease 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00107 💬 Tacrolimus 34件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
21 Alzheimer disease 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D08556 💬 Tacrolimus 34件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
22 Alzheimer disease 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
23 Amoebiasis 💬
 2件: IL6, TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
24 Amoebiasis 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
25 Amphetamine addiction 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00107 💬 Tacrolimus 34件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
26 Amphetamine addiction 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D08556 💬 Tacrolimus 34件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
27 Amyotrophic lateral sclerosis 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00107 💬 Tacrolimus 34件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
28 Amyotrophic lateral sclerosis 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D08556 💬 Tacrolimus 34件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
29 Amyotrophic lateral sclerosis 💬
 1件: TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
30 Amyotrophic lateral sclerosis 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
31 Antifolate resistance 💬
 2件: IL6, TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
32 Antifolate resistance 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
33 Antigen processing and presentation 💬
 1件: TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
34 Antigen processing and presentation 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
35 Apoptosis 💬
 1件: TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
36 Apoptosis 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
37 Asthma 💬
 1件: TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
38 Asthma 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
39 Axon guidance 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00107 💬 Tacrolimus 34件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
40 Axon guidance 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D08556 💬 Tacrolimus 34件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
41 B cell receptor signaling pathway 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00107 💬 Tacrolimus 34件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
42 B cell receptor signaling pathway 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D08556 💬 Tacrolimus 34件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
43 Bladder cancer 💬
 1件: FGFR3 💬 D10481 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
44 Bladder cancer 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
45 Bladder cancer 💬
 1件: VEGFA 💬 D05697 💬 Ranibizumab 4件: 34, 166, 227, 301 💬
46 Breast cancer 💬
 2件: ESR1, ESR2 💬 D00185 💬 Estriol 2件: 13, 227 💬
47 Breast cancer 💬
 2件: ESR1, ESR2 💬 D01986 💬 Estriol 2件: 13, 227 💬
48 Breast cancer 💬
 2件: ESR1, ESR2 💬 D00966 💬 Tamoxifen 4件:  2 , 86, 113, 227 💬
49 Breast cancer 💬
 2件: ESR1, ESR2 💬 D08559 💬 Tamoxifen 4件:  2 , 86, 113, 227 💬
50 Breast cancer 💬
 2件: FGFR1, FLT4 💬 D10481 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
51 C-type lectin receptor signaling pathway 💬
 2件: IL6, TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
52 C-type lectin receptor signaling pathway 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00107 💬 Tacrolimus 34件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
53 C-type lectin receptor signaling pathway 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D08556 💬 Tacrolimus 34件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
54 C-type lectin receptor signaling pathway 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
55 Calcium signaling pathway 💬
 2件: ADRB1, ADRB2 💬 D00378 💬 Timolol 2件: 157, 227 💬
56 Calcium signaling pathway 💬
 2件: ADRB1, ADRB2 💬 D00603 💬 Timolol 2件: 157, 227 💬
57 Calcium signaling pathway 💬
 2件: ADRB1, ADRB2 💬 D08600 💬 Timolol 2件: 157, 227 💬
58 Calcium signaling pathway 💬
 3件: ADRB1, ADRB2, ADRB3 💬 D00483 💬 Propranolol 7件:  6 , 158, 167, 215, 227, 278, 296 💬
59 Calcium signaling pathway 💬
 3件: ADRB1, ADRB2, ADRB3 💬 D08443 💬 Propranolol 7件:  6 , 158, 167, 215, 227, 278, 296 💬
60 Calcium signaling pathway 💬
 8件: FGFR1, FGFR2, FGFR3, FLT1, FLT4, KDR, PDGFRA, PDGFRB 💬 D10481 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
61 Calcium signaling pathway 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00107 💬 Tacrolimus 34件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
62 Calcium signaling pathway 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D08556 💬 Tacrolimus 34件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
63 Calcium signaling pathway 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
64 Calcium signaling pathway 💬
 1件: VEGFA 💬 D05697 💬 Ranibizumab 4件: 34, 166, 227, 301 💬
65 cAMP signaling pathway 💬
 2件: ADRB1, ADRB2 💬 D00483 💬 Propranolol 7件:  6 , 158, 167, 215, 227, 278, 296 💬
66 cAMP signaling pathway 💬
 2件: ADRB1, ADRB2 💬 D08443 💬 Propranolol 7件:  6 , 158, 167, 215, 227, 278, 296 💬
67 cAMP signaling pathway 💬
 2件: ADRB1, ADRB2 💬 D00378 💬 Timolol 2件: 157, 227 💬
68 cAMP signaling pathway 💬
 2件: ADRB1, ADRB2 💬 D00603 💬 Timolol 2件: 157, 227 💬
69 cAMP signaling pathway 💬
 2件: ADRB1, ADRB2 💬 D08600 💬 Timolol 2件: 157, 227 💬
70 cAMP signaling pathway 💬
 1件: SSTR2 💬 D00442 💬 Octreotide 7件: 67, 75, 84, 85, 89, 193, 227 💬
71 cAMP signaling pathway 💬
 1件: SSTR2 💬 D06495 💬 Octreotide 7件: 67, 75, 84, 85, 89, 193, 227 💬
72 Cellular senescence 💬
 1件: IL6 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
73 Cellular senescence 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00107 💬 Tacrolimus 34件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
74 Cellular senescence 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D08556 💬 Tacrolimus 34件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
75 Central carbon metabolism in cancer 💬
 5件: FGFR1, FGFR2, FGFR3, PDGFRA, PDGFRB 💬 D10481 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
76 cGMP-PKG signaling pathway 💬
 2件: ADRB1, ADRB2 💬 D00378 💬 Timolol 2件: 157, 227 💬
77 cGMP-PKG signaling pathway 💬
 2件: ADRB1, ADRB2 💬 D00603 💬 Timolol 2件: 157, 227 💬
78 cGMP-PKG signaling pathway 💬
 2件: ADRB1, ADRB2 💬 D08600 💬 Timolol 2件: 157, 227 💬
79 cGMP-PKG signaling pathway 💬
 3件: ADRB1, ADRB2, ADRB3 💬 D00483 💬 Propranolol 7件:  6 , 158, 167, 215, 227, 278, 296 💬
80 cGMP-PKG signaling pathway 💬
 3件: ADRB1, ADRB2, ADRB3 💬 D08443 💬 Propranolol 7件:  6 , 158, 167, 215, 227, 278, 296 💬
81 cGMP-PKG signaling pathway 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00107 💬 Tacrolimus 34件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
82 cGMP-PKG signaling pathway 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D08556 💬 Tacrolimus 34件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
83 Chagas disease 💬
 2件: IL6, TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
84 Chagas disease 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
85 Chemical carcinogenesis - reactive oxygen species 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
86 Chemical carcinogenesis - reactive oxygen species 💬
 1件: VEGFA 💬 D05697 💬 Ranibizumab 4件: 34, 166, 227, 301 💬
87 Chemical carcinogenesis - receptor activation 💬
 2件: ADRB1, ADRB2 💬 D00378 💬 Timolol 2件: 157, 227 💬
88 Chemical carcinogenesis - receptor activation 💬
 2件: ADRB1, ADRB2 💬 D00603 💬 Timolol 2件: 157, 227 💬
89 Chemical carcinogenesis - receptor activation 💬
 2件: ADRB1, ADRB2 💬 D08600 💬 Timolol 2件: 157, 227 💬
90 Chemical carcinogenesis - receptor activation 💬
 3件: ADRB1, ADRB2, ADRB3 💬 D00483 💬 Propranolol 7件:  6 , 158, 167, 215, 227, 278, 296 💬
91 Chemical carcinogenesis - receptor activation 💬
 3件: ADRB1, ADRB2, ADRB3 💬 D08443 💬 Propranolol 7件:  6 , 158, 167, 215, 227, 278, 296 💬
92 Chemical carcinogenesis - receptor activation 💬
 2件: ESR1, ESR2 💬 D00185 💬 Estriol 2件: 13, 227 💬
93 Chemical carcinogenesis - receptor activation 💬
 2件: ESR1, ESR2 💬 D01986 💬 Estriol 2件: 13, 227 💬
94 Chemical carcinogenesis - receptor activation 💬
 2件: ESR1, ESR2 💬 D00966 💬 Tamoxifen 4件:  2 , 86, 113, 227 💬
95 Chemical carcinogenesis - receptor activation 💬
 2件: ESR1, ESR2 💬 D08559 💬 Tamoxifen 4件:  2 , 86, 113, 227 💬
96 Chemical carcinogenesis - receptor activation 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
97 Chemical carcinogenesis - receptor activation 💬
 1件: VEGFA 💬 D05697 💬 Ranibizumab 4件: 34, 166, 227, 301 💬
98 Choline metabolism in cancer 💬
 2件: PDGFRA, PDGFRB 💬 D10481 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
99 Complement and coagulation cascades 💬
 1件: PLG 💬 D01136 💬 Tranexamic acid 6件: 46, 70, 215, 227, 288, 299 💬
100 Coronavirus disease - COVID-19 💬
 2件: IL6, TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
101 Coronavirus disease - COVID-19 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
102 Cytokine-cytokine receptor interaction 💬
 2件: IL6, TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
103 Cytokine-cytokine receptor interaction 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
104 Cytosolic DNA-sensing pathway 💬
 1件: IL6 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
105 Dilated cardiomyopathy 💬
 1件: ADRB1 💬 D00483 💬 Propranolol 7件:  6 , 158, 167, 215, 227, 278, 296 💬
106 Dilated cardiomyopathy 💬
 1件: ADRB1 💬 D08443 💬 Propranolol 7件:  6 , 158, 167, 215, 227, 278, 296 💬
107 Dilated cardiomyopathy 💬
 1件: ADRB1 💬 D00378 💬 Timolol 2件: 157, 227 💬
108 Dilated cardiomyopathy 💬
 1件: ADRB1 💬 D00603 💬 Timolol 2件: 157, 227 💬
109 Dilated cardiomyopathy 💬
 1件: ADRB1 💬 D08600 💬 Timolol 2件: 157, 227 💬
110 Dilated cardiomyopathy 💬
 1件: TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
111 Dilated cardiomyopathy 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
112 Dopaminergic synapse 💬
 3件: PPP3CA, PPP3CB, PPP3CC 💬 D00107 💬 Tacrolimus 34件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
113 Dopaminergic synapse 💬
 3件: PPP3CA, PPP3CB, PPP3CC 💬 D08556 💬 Tacrolimus 34件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
114 EGFR tyrosine kinase inhibitor resistance 💬
 5件: FGFR2, FGFR3, KDR, PDGFRA, PDGFRB 💬 D10481 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
115 EGFR tyrosine kinase inhibitor resistance 💬
 1件: IL6 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
116 EGFR tyrosine kinase inhibitor resistance 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
117 EGFR tyrosine kinase inhibitor resistance 💬
 1件: VEGFA 💬 D05697 💬 Ranibizumab 4件: 34, 166, 227, 301 💬
118 Endocrine and other factor-regulated calcium reabsorption 💬
 1件: ESR1 💬 D00185 💬 Estriol 2件: 13, 227 💬
119 Endocrine and other factor-regulated calcium reabsorption 💬
 1件: ESR1 💬 D01986 💬 Estriol 2件: 13, 227 💬
120 Endocrine and other factor-regulated calcium reabsorption 💬
 1件: ESR1 💬 D00966 💬 Tamoxifen 4件:  2 , 86, 113, 227 💬
121 Endocrine and other factor-regulated calcium reabsorption 💬
 1件: ESR1 💬 D08559 💬 Tamoxifen 4件:  2 , 86, 113, 227 💬
122 Endocrine resistance 💬
 2件: ESR1, ESR2 💬 D00185 💬 Estriol 2件: 13, 227 💬
123 Endocrine resistance 💬
 2件: ESR1, ESR2 💬 D01986 💬 Estriol 2件: 13, 227 💬
124 Endocrine resistance 💬
 2件: ESR1, ESR2 💬 D00966 💬 Tamoxifen 4件:  2 , 86, 113, 227 💬
125 Endocrine resistance 💬
 2件: ESR1, ESR2 💬 D08559 💬 Tamoxifen 4件:  2 , 86, 113, 227 💬
126 Endocytosis 💬
 3件: FGFR2, FGFR3, PDGFRA 💬 D10481 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
127 Epstein-Barr virus infection 💬
 2件: IL6, TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
128 Epstein-Barr virus infection 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
129 Estrogen signaling pathway 💬
 2件: ESR1, ESR2 💬 D00185 💬 Estriol 2件: 13, 227 💬
130 Estrogen signaling pathway 💬
 2件: ESR1, ESR2 💬 D01986 💬 Estriol 2件: 13, 227 💬
131 Estrogen signaling pathway 💬
 2件: ESR1, ESR2 💬 D00966 💬 Tamoxifen 4件:  2 , 86, 113, 227 💬
132 Estrogen signaling pathway 💬
 2件: ESR1, ESR2 💬 D08559 💬 Tamoxifen 4件:  2 , 86, 113, 227 💬
133 Fc epsilon RI signaling pathway 💬
 1件: TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
134 Fc epsilon RI signaling pathway 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
135 Fluid shear stress and atherosclerosis 💬
 1件: KDR 💬 D10481 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
136 Fluid shear stress and atherosclerosis 💬
 1件: TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
137 Fluid shear stress and atherosclerosis 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
138 Fluid shear stress and atherosclerosis 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
139 Fluid shear stress and atherosclerosis 💬
 1件: VEGFA 💬 D05697 💬 Ranibizumab 4件: 34, 166, 227, 301 💬
140 Focal adhesion 💬
 5件: FLT1, FLT4, KDR, PDGFRA, PDGFRB 💬 D10481 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
141 Focal adhesion 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
142 Focal adhesion 💬
 1件: VEGFA 💬 D05697 💬 Ranibizumab 4件: 34, 166, 227, 301 💬
143 FoxO signaling pathway 💬
 1件: IL6 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
144 Gap junction 💬
 1件: ADRB1 💬 D00483 💬 Propranolol 7件:  6 , 158, 167, 215, 227, 278, 296 💬
145 Gap junction 💬
 1件: ADRB1 💬 D08443 💬 Propranolol 7件:  6 , 158, 167, 215, 227, 278, 296 💬
146 Gap junction 💬
 1件: ADRB1 💬 D00378 💬 Timolol 2件: 157, 227 💬
147 Gap junction 💬
 1件: ADRB1 💬 D00603 💬 Timolol 2件: 157, 227 💬
148 Gap junction 💬
 1件: ADRB1 💬 D08600 💬 Timolol 2件: 157, 227 💬
149 Gap junction 💬
 2件: PDGFRA, PDGFRB 💬 D10481 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
150 Gastric acid secretion 💬
 1件: SSTR2 💬 D00442 💬 Octreotide 7件: 67, 75, 84, 85, 89, 193, 227 💬
151 Gastric acid secretion 💬
 1件: SSTR2 💬 D06495 💬 Octreotide 7件: 67, 75, 84, 85, 89, 193, 227 💬
152 Gastric cancer 💬
 1件: FGFR2 💬 D10481 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
153 Glioma 💬
 2件: PDGFRA, PDGFRB 💬 D10481 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
154 Glucagon signaling pathway 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00107 💬 Tacrolimus 34件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
155 Glucagon signaling pathway 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D08556 💬 Tacrolimus 34件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
156 Glutamatergic synapse 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00107 💬 Tacrolimus 34件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
157 Glutamatergic synapse 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D08556 💬 Tacrolimus 34件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
158 GnRH secretion 💬
 1件: ESR2 💬 D00185 💬 Estriol 2件: 13, 227 💬
159 GnRH secretion 💬
 1件: ESR2 💬 D01986 💬 Estriol 2件: 13, 227 💬
160 GnRH secretion 💬
 1件: ESR2 💬 D00966 💬 Tamoxifen 4件:  2 , 86, 113, 227 💬
161 GnRH secretion 💬
 1件: ESR2 💬 D08559 💬 Tamoxifen 4件:  2 , 86, 113, 227 💬
162 Graft-versus-host disease 💬
 2件: IL6, TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
163 Graft-versus-host disease 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
164 Growth hormone synthesis, secretion and action 💬
 1件: SSTR2 💬 D00442 💬 Octreotide 7件: 67, 75, 84, 85, 89, 193, 227 💬
165 Growth hormone synthesis, secretion and action 💬
 1件: SSTR2 💬 D06495 💬 Octreotide 7件: 67, 75, 84, 85, 89, 193, 227 💬
166 Hematopoietic cell lineage 💬
 2件: IL6, TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
167 Hematopoietic cell lineage 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
168 Hepatitis B 💬
 2件: IL6, TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
169 Hepatitis B 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
170 Hepatitis C 💬
 1件: TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
171 Hepatitis C 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
172 Herpes simplex virus 1 infection 💬
 2件: IL6, TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
173 Herpes simplex virus 1 infection 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
174 HIF-1 signaling pathway 💬
 1件: FLT1 💬 D10481 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
175 HIF-1 signaling pathway 💬
 1件: IL6 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
176 HIF-1 signaling pathway 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
177 HIF-1 signaling pathway 💬
 1件: VEGFA 💬 D05697 💬 Ranibizumab 4件: 34, 166, 227, 301 💬
178 Human cytomegalovirus infection 💬
 2件: IL6, TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
179 Human cytomegalovirus infection 💬
 1件: PDGFRA 💬 D10481 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
180 Human cytomegalovirus infection 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00107 💬 Tacrolimus 34件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
181 Human cytomegalovirus infection 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D08556 💬 Tacrolimus 34件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
182 Human cytomegalovirus infection 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
183 Human cytomegalovirus infection 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
184 Human cytomegalovirus infection 💬
 1件: VEGFA 💬 D05697 💬 Ranibizumab 4件: 34, 166, 227, 301 💬
185 Human immunodeficiency virus 1 infection 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00107 💬 Tacrolimus 34件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
186 Human immunodeficiency virus 1 infection 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D08556 💬 Tacrolimus 34件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
187 Human immunodeficiency virus 1 infection 💬
 1件: TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
188 Human immunodeficiency virus 1 infection 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
189 Human papillomavirus infection 💬
 1件: PDGFRB 💬 D10481 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
190 Human papillomavirus infection 💬
 1件: TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
191 Human papillomavirus infection 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
192 Human papillomavirus infection 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
193 Human papillomavirus infection 💬
 1件: VEGFA 💬 D05697 💬 Ranibizumab 4件: 34, 166, 227, 301 💬
194 Human T-cell leukemia virus 1 infection 💬
 2件: IL6, TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
195 Human T-cell leukemia virus 1 infection 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00107 💬 Tacrolimus 34件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
196 Human T-cell leukemia virus 1 infection 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D08556 💬 Tacrolimus 34件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
197 Human T-cell leukemia virus 1 infection 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
198 Hypertrophic cardiomyopathy 💬
 2件: IL6, TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
199 Hypertrophic cardiomyopathy 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
200 IL-17 signaling pathway 💬
 2件: IL6, TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
201 IL-17 signaling pathway 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
202 Inflammatory bowel disease 💬
 2件: IL6, TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
203 Inflammatory bowel disease 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
204 Influenza A 💬
 2件: IL6, TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
205 Influenza A 💬
 1件: PLG 💬 D01136 💬 Tranexamic acid 6件: 46, 70, 215, 227, 288, 299 💬
206 Influenza A 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
207 Insulin resistance 💬
 2件: IL6, TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
208 Insulin resistance 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
209 Intestinal immune network for IgA production 💬
 1件: IL6 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
210 JAK-STAT signaling pathway 💬
 1件: IL6 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
211 JAK-STAT signaling pathway 💬
 2件: PDGFRA, PDGFRB 💬 D10481 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
212 Kaposi sarcoma-associated herpesvirus infection 💬
 1件: IL6 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
213 Kaposi sarcoma-associated herpesvirus infection 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00107 💬 Tacrolimus 34件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
214 Kaposi sarcoma-associated herpesvirus infection 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D08556 💬 Tacrolimus 34件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
215 Kaposi sarcoma-associated herpesvirus infection 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
216 Kaposi sarcoma-associated herpesvirus infection 💬
 1件: VEGFA 💬 D05697 💬 Ranibizumab 4件: 34, 166, 227, 301 💬
217 Legionellosis 💬
 2件: IL6, TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
218 Legionellosis 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
219 Leishmaniasis 💬
 1件: TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
220 Leishmaniasis 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
221 Lipid and atherosclerosis 💬
 2件: IL6, TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
222 Lipid and atherosclerosis 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00107 💬 Tacrolimus 34件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
223 Lipid and atherosclerosis 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D08556 💬 Tacrolimus 34件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
224 Lipid and atherosclerosis 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
225 Long-term potentiation 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00107 💬 Tacrolimus 34件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
226 Long-term potentiation 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D08556 💬 Tacrolimus 34件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
227 Malaria 💬
 2件: IL6, TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
228 Malaria 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
229 MAPK signaling pathway 💬
 8件: FGFR1, FGFR2, FGFR3, FLT1, FLT4, KDR, PDGFRA, PDGFRB 💬 D10481 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
230 MAPK signaling pathway 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00107 💬 Tacrolimus 34件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
231 MAPK signaling pathway 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D08556 💬 Tacrolimus 34件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
232 MAPK signaling pathway 💬
 1件: TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
233 MAPK signaling pathway 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
234 MAPK signaling pathway 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
235 MAPK signaling pathway 💬
 1件: VEGFA 💬 D05697 💬 Ranibizumab 4件: 34, 166, 227, 301 💬
236 Measles 💬
 1件: IL6 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
237 Melanoma 💬
 3件: FGFR1, PDGFRA, PDGFRB 💬 D10481 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
238 MicroRNAs in cancer 💬
 3件: FGFR3, PDGFRA, PDGFRB 💬 D10481 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
239 MicroRNAs in cancer 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
240 MicroRNAs in cancer 💬
 1件: VEGFA 💬 D05697 💬 Ranibizumab 4件: 34, 166, 227, 301 💬
241 mTOR signaling pathway 💬
 1件: TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
242 mTOR signaling pathway 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
243 Natural killer cell mediated cytotoxicity 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00107 💬 Tacrolimus 34件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
244 Natural killer cell mediated cytotoxicity 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D08556 💬 Tacrolimus 34件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
245 Natural killer cell mediated cytotoxicity 💬
 1件: TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
246 Natural killer cell mediated cytotoxicity 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
247 Necroptosis 💬
 1件: TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
248 Necroptosis 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
249 Neuroactive ligand-receptor interaction 💬
 2件: ADRB1, ADRB2 💬 D00378 💬 Timolol 2件: 157, 227 💬
250 Neuroactive ligand-receptor interaction 💬
 2件: ADRB1, ADRB2 💬 D00603 💬 Timolol 2件: 157, 227 💬
251 Neuroactive ligand-receptor interaction 💬
 2件: ADRB1, ADRB2 💬 D08600 💬 Timolol 2件: 157, 227 💬
252 Neuroactive ligand-receptor interaction 💬
 3件: ADRB1, ADRB2, ADRB3 💬 D00483 💬 Propranolol 7件:  6 , 158, 167, 215, 227, 278, 296 💬
253 Neuroactive ligand-receptor interaction 💬
 3件: ADRB1, ADRB2, ADRB3 💬 D08443 💬 Propranolol 7件:  6 , 158, 167, 215, 227, 278, 296 💬
254 Neuroactive ligand-receptor interaction 💬
 1件: PLG 💬 D01136 💬 Tranexamic acid 6件: 46, 70, 215, 227, 288, 299 💬
255 Neuroactive ligand-receptor interaction 💬
 1件: SSTR2 💬 D00442 💬 Octreotide 7件: 67, 75, 84, 85, 89, 193, 227 💬
256 Neuroactive ligand-receptor interaction 💬
 1件: SSTR2 💬 D06495 💬 Octreotide 7件: 67, 75, 84, 85, 89, 193, 227 💬
257 NF-kappa B signaling pathway 💬
 1件: TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
258 NF-kappa B signaling pathway 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
259 NOD-like receptor signaling pathway 💬
 2件: IL6, TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
260 NOD-like receptor signaling pathway 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
261 Non-alcoholic fatty liver disease 💬
 2件: IL6, TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
262 Non-alcoholic fatty liver disease 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
263 Oocyte meiosis 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00107 💬 Tacrolimus 34件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
264 Oocyte meiosis 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D08556 💬 Tacrolimus 34件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
265 Osteoclast differentiation 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00107 💬 Tacrolimus 34件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
266 Osteoclast differentiation 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D08556 💬 Tacrolimus 34件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
267 Osteoclast differentiation 💬
 1件: TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
268 Osteoclast differentiation 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
269 Oxytocin signaling pathway 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00107 💬 Tacrolimus 34件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
270 Oxytocin signaling pathway 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D08556 💬 Tacrolimus 34件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
271 Pancreatic cancer 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
272 Pancreatic cancer 💬
 1件: VEGFA 💬 D05697 💬 Ranibizumab 4件: 34, 166, 227, 301 💬
273 Parathyroid hormone synthesis, secretion and action 💬
 1件: FGFR1 💬 D10481 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
274 Pathogenic Escherichia coli infection 💬
 2件: IL6, TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
275 Pathogenic Escherichia coli infection 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
276 Pathways in cancer 💬
 2件: ESR1, ESR2 💬 D00185 💬 Estriol 2件: 13, 227 💬
277 Pathways in cancer 💬
 2件: ESR1, ESR2 💬 D01986 💬 Estriol 2件: 13, 227 💬
278 Pathways in cancer 💬
 2件: ESR1, ESR2 💬 D00966 💬 Tamoxifen 4件:  2 , 86, 113, 227 💬
279 Pathways in cancer 💬
 2件: ESR1, ESR2 💬 D08559 💬 Tamoxifen 4件:  2 , 86, 113, 227 💬
280 Pathways in cancer 💬
 6件: FGFR1, FGFR2, FGFR3, FLT4, PDGFRA, PDGFRB 💬 D10481 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
281 Pathways in cancer 💬
 1件: IL6 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
282 Pathways in cancer 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
283 Pathways in cancer 💬
 1件: VEGFA 💬 D05697 💬 Ranibizumab 4件: 34, 166, 227, 301 💬
284 Pathways of neurodegeneration - multiple diseases 💬
 2件: IL6, TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
285 Pathways of neurodegeneration - multiple diseases 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00107 💬 Tacrolimus 34件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
286 Pathways of neurodegeneration - multiple diseases 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D08556 💬 Tacrolimus 34件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
287 Pathways of neurodegeneration - multiple diseases 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
288 PD-L1 expression and PD-1 checkpoint pathway in cancer 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00107 💬 Tacrolimus 34件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
289 PD-L1 expression and PD-1 checkpoint pathway in cancer 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D08556 💬 Tacrolimus 34件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
290 Pertussis 💬
 2件: IL6, TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
291 Pertussis 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
292 Phospholipase D signaling pathway 💬
 2件: PDGFRA, PDGFRB 💬 D10481 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
293 PI3K-Akt signaling pathway 💬
 8件: FGFR1, FGFR2, FGFR3, FLT1, FLT4, KDR, PDGFRA, PDGFRB 💬 D10481 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
294 PI3K-Akt signaling pathway 💬
 1件: IL6 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
295 PI3K-Akt signaling pathway 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
296 PI3K-Akt signaling pathway 💬
 1件: VEGFA 💬 D05697 💬 Ranibizumab 4件: 34, 166, 227, 301 💬
297 Prion disease 💬
 2件: IL6, TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
298 Prion disease 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00107 💬 Tacrolimus 34件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
299 Prion disease 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D08556 💬 Tacrolimus 34件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
300 Prion disease 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
301 Prolactin signaling pathway 💬
 2件: ESR1, ESR2 💬 D00185 💬 Estriol 2件: 13, 227 💬
302 Prolactin signaling pathway 💬
 2件: ESR1, ESR2 💬 D01986 💬 Estriol 2件: 13, 227 💬
303 Prolactin signaling pathway 💬
 2件: ESR1, ESR2 💬 D00966 💬 Tamoxifen 4件:  2 , 86, 113, 227 💬
304 Prolactin signaling pathway 💬
 2件: ESR1, ESR2 💬 D08559 💬 Tamoxifen 4件:  2 , 86, 113, 227 💬
305 Prostate cancer 💬
 4件: FGFR1, FGFR2, PDGFRA, PDGFRB 💬 D10481 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
306 Proteoglycans in cancer 💬
 1件: ESR1 💬 D00185 💬 Estriol 2件: 13, 227 💬
307 Proteoglycans in cancer 💬
 1件: ESR1 💬 D01986 💬 Estriol 2件: 13, 227 💬
308 Proteoglycans in cancer 💬
 1件: ESR1 💬 D00966 💬 Tamoxifen 4件:  2 , 86, 113, 227 💬
309 Proteoglycans in cancer 💬
 1件: ESR1 💬 D08559 💬 Tamoxifen 4件:  2 , 86, 113, 227 💬
310 Proteoglycans in cancer 💬
 2件: FGFR1, KDR 💬 D10481 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
311 Proteoglycans in cancer 💬
 1件: TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
312 Proteoglycans in cancer 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
313 Proteoglycans in cancer 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
314 Proteoglycans in cancer 💬
 1件: VEGFA 💬 D05697 💬 Ranibizumab 4件: 34, 166, 227, 301 💬
315 Rap1 signaling pathway 💬
 8件: FGFR1, FGFR2, FGFR3, FLT1, FLT4, KDR, PDGFRA, PDGFRB 💬 D10481 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
316 Rap1 signaling pathway 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
317 Rap1 signaling pathway 💬
 1件: VEGFA 💬 D05697 💬 Ranibizumab 4件: 34, 166, 227, 301 💬
318 Ras signaling pathway 💬
 8件: FGFR1, FGFR2, FGFR3, FLT1, FLT4, KDR, PDGFRA, PDGFRB 💬 D10481 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
319 Ras signaling pathway 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
320 Ras signaling pathway 💬
 1件: VEGFA 💬 D05697 💬 Ranibizumab 4件: 34, 166, 227, 301 💬
321 Regulation of actin cytoskeleton 💬
 5件: FGFR1, FGFR2, FGFR3, PDGFRA, PDGFRB 💬 D10481 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
322 Regulation of lipolysis in adipocytes 💬
 2件: ADRB1, ADRB2 💬 D00378 💬 Timolol 2件: 157, 227 💬
323 Regulation of lipolysis in adipocytes 💬
 2件: ADRB1, ADRB2 💬 D00603 💬 Timolol 2件: 157, 227 💬
324 Regulation of lipolysis in adipocytes 💬
 2件: ADRB1, ADRB2 💬 D08600 💬 Timolol 2件: 157, 227 💬
325 Regulation of lipolysis in adipocytes 💬
 3件: ADRB1, ADRB2, ADRB3 💬 D00483 💬 Propranolol 7件:  6 , 158, 167, 215, 227, 278, 296 💬
326 Regulation of lipolysis in adipocytes 💬
 3件: ADRB1, ADRB2, ADRB3 💬 D08443 💬 Propranolol 7件:  6 , 158, 167, 215, 227, 278, 296 💬
327 Relaxin signaling pathway 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
328 Relaxin signaling pathway 💬
 1件: VEGFA 💬 D05697 💬 Ranibizumab 4件: 34, 166, 227, 301 💬
329 Renal cell carcinoma 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
330 Renal cell carcinoma 💬
 1件: VEGFA 💬 D05697 💬 Ranibizumab 4件: 34, 166, 227, 301 💬
331 Renin secretion 💬
 2件: ADRB1, ADRB2 💬 D00378 💬 Timolol 2件: 157, 227 💬
332 Renin secretion 💬
 2件: ADRB1, ADRB2 💬 D00603 💬 Timolol 2件: 157, 227 💬
333 Renin secretion 💬
 2件: ADRB1, ADRB2 💬 D08600 💬 Timolol 2件: 157, 227 💬
334 Renin secretion 💬
 3件: ADRB1, ADRB2, ADRB3 💬 D00483 💬 Propranolol 7件:  6 , 158, 167, 215, 227, 278, 296 💬
335 Renin secretion 💬
 3件: ADRB1, ADRB2, ADRB3 💬 D08443 💬 Propranolol 7件:  6 , 158, 167, 215, 227, 278, 296 💬
336 Renin secretion 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00107 💬 Tacrolimus 34件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
337 Renin secretion 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D08556 💬 Tacrolimus 34件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
338 Rheumatoid arthritis 💬
 1件: FLT1 💬 D10481 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
339 Rheumatoid arthritis 💬
 2件: IL6, TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
340 Rheumatoid arthritis 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
341 Rheumatoid arthritis 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
342 Rheumatoid arthritis 💬
 1件: VEGFA 💬 D05697 💬 Ranibizumab 4件: 34, 166, 227, 301 💬
343 RIG-I-like receptor signaling pathway 💬
 1件: TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
344 RIG-I-like receptor signaling pathway 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
345 Salivary secretion 💬
 2件: ADRB1, ADRB2 💬 D00378 💬 Timolol 2件: 157, 227 💬
346 Salivary secretion 💬
 2件: ADRB1, ADRB2 💬 D00603 💬 Timolol 2件: 157, 227 💬
347 Salivary secretion 💬
 2件: ADRB1, ADRB2 💬 D08600 💬 Timolol 2件: 157, 227 💬
348 Salivary secretion 💬
 3件: ADRB1, ADRB2, ADRB3 💬 D00483 💬 Propranolol 7件:  6 , 158, 167, 215, 227, 278, 296 💬
349 Salivary secretion 💬
 3件: ADRB1, ADRB2, ADRB3 💬 D08443 💬 Propranolol 7件:  6 , 158, 167, 215, 227, 278, 296 💬
350 Salmonella infection 💬
 2件: IL6, TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
351 Salmonella infection 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
352 Shigellosis 💬
 1件: TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
353 Shigellosis 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
354 Signaling pathways regulating pluripotency of stem cells 💬
 3件: FGFR1, FGFR2, FGFR3 💬 D10481 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
355 Sphingolipid signaling pathway 💬
 1件: TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
356 Sphingolipid signaling pathway 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
357 Staphylococcus aureus infection 💬
 1件: PLG 💬 D01136 💬 Tranexamic acid 6件: 46, 70, 215, 227, 288, 299 💬
358 Systemic lupus erythematosus 💬
 1件: TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
359 Systemic lupus erythematosus 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
360 T cell receptor signaling pathway 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00107 💬 Tacrolimus 34件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
361 T cell receptor signaling pathway 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D08556 💬 Tacrolimus 34件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
362 T cell receptor signaling pathway 💬
 1件: TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
363 T cell receptor signaling pathway 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
364 TGF-beta signaling pathway 💬
 1件: TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
365 TGF-beta signaling pathway 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
366 Th1 and Th2 cell differentiation 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00107 💬 Tacrolimus 34件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
367 Th1 and Th2 cell differentiation 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D08556 💬 Tacrolimus 34件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
368 Th17 cell differentiation 💬
 1件: IL6 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
369 Th17 cell differentiation 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00107 💬 Tacrolimus 34件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
370 Th17 cell differentiation 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D08556 💬 Tacrolimus 34件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
371 Thermogenesis 💬
 1件: ADRB3 💬 D00483 💬 Propranolol 7件:  6 , 158, 167, 215, 227, 278, 296 💬
372 Thermogenesis 💬
 1件: ADRB3 💬 D08443 💬 Propranolol 7件:  6 , 158, 167, 215, 227, 278, 296 💬
373 Thermogenesis 💬
 1件: FGFR1 💬 D10481 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
374 Thyroid hormone signaling pathway 💬
 1件: ESR1 💬 D00185 💬 Estriol 2件: 13, 227 💬
375 Thyroid hormone signaling pathway 💬
 1件: ESR1 💬 D01986 💬 Estriol 2件: 13, 227 💬
376 Thyroid hormone signaling pathway 💬
 1件: ESR1 💬 D00966 💬 Tamoxifen 4件:  2 , 86, 113, 227 💬
377 Thyroid hormone signaling pathway 💬
 1件: ESR1 💬 D08559 💬 Tamoxifen 4件:  2 , 86, 113, 227 💬
378 TNF signaling pathway 💬
 2件: IL6, TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
379 TNF signaling pathway 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
380 Toll-like receptor signaling pathway 💬
 2件: IL6, TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
381 Toll-like receptor signaling pathway 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
382 Toxoplasmosis 💬
 1件: TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
383 Toxoplasmosis 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
384 Transcriptional misregulation in cancer 💬
 1件: FLT1 💬 D10481 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
385 Transcriptional misregulation in cancer 💬
 1件: IL6 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
386 Tuberculosis 💬
 2件: IL6, TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
387 Tuberculosis 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00107 💬 Tacrolimus 34件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
388 Tuberculosis 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D08556 💬 Tacrolimus 34件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
389 Tuberculosis 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
390 Type I diabetes mellitus 💬
 1件: TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
391 Type I diabetes mellitus 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
392 Type II diabetes mellitus 💬
 1件: TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
393 Type II diabetes mellitus 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
394 VEGF signaling pathway 💬
 1件: KDR 💬 D10481 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
395 VEGF signaling pathway 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00107 💬 Tacrolimus 34件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
396 VEGF signaling pathway 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D08556 💬 Tacrolimus 34件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
397 VEGF signaling pathway 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
398 VEGF signaling pathway 💬
 1件: VEGFA 💬 D05697 💬 Ranibizumab 4件: 34, 166, 227, 301 💬
399 Viral protein interaction with cytokine and cytokine receptor 💬
 2件: IL6, TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
400 Viral protein interaction with cytokine and cytokine receptor 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
401 Wnt signaling pathway 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00107 💬 Tacrolimus 34件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
402 Wnt signaling pathway 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D08556 💬 Tacrolimus 34件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
403 Yersinia infection 💬
 2件: IL6, TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
404 Yersinia infection 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬

先頭へ